ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 927,62
0,44%
Dow Jones
44 397,52
-0,38%
DAX
21 394,93
-0,11%
Brent Oil
77,625
0,38%
Bitcoin
106 289,44
2,24%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Recursion Pharmaceuticals Inc (RXRX) Cours

Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc (RXRX)

NASDAQ
7,505
-0,025
( -0,33% )
Mis à jour : 20:20:45
Retardé de 15 minutes

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
7,505
Prix Achat
7,50
Prix Vente
7,51
Volume échangé
18 875 760
7,48 Fourchette du Jour 8,26
5,61 Plage de 52 semaines 15,74
Cap du marché
2,151B
Clôture Veille
7,53
Ouverture
7,64
Dernière Transaction
1
@
7.5075
Dernière heure de transaction
20:20:50
Volume financier
US$ 148 594 354
VWAP
7,8722
Volume moyen (3 m)
13 753 586
Actions en circulation
286 640 833
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-6,67
Bénéfice par action (BPA)
-1,14
Chiffre d'affairess
44,58M
Bénéfice net
-328,07M

À propos de Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery... Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Show more

Secteur
Biological Pds,ex Diagnstics
Industrie
Biological Pds,ex Diagnstics
Site Web
www.recursion.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Recursion Pharmaceuticals Inc est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker RXRX. Le dernier cours de clôture d'Recursion Pharmaceuticals était de US$7,53. Au cours de la dernière année, les actions de Recursion Pharmaceuticals ont été négociées dans une fourchette de prix de US$ 5,61 à US$ 15,74.

Recursion Pharmaceuticals compte actuellement 286 640 833 actions en circulation. La capitalisation boursière d'Recursion Pharmaceuticals est de US$2,16 milliard. Recursion Pharmaceuticals a un ratio cours/bénéfice (ratio PE) de -6.67.

Flux d'options Recursion Pharmaceuticals (RXRX)

Voir le flux d'options complet

Flux global

Haussier

Prime nette

782k

Calls / Puts

550,00%

Ach. / Vent.

166,67%

OTM / ITM

44,44%

Sweeps Ratio

0,00%

RXRX Dernières nouvelles

Plus de nouvelles

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028 PR Newswire VANCOUVER, BC, Jan. 17, 2025 USA News Group News Commentary  Issued on behalf of Avant Technologies...

17 Janvier 2025
PR Newswire (US)

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028 PR Newswire VANCOUVER, BC, Jan. 17, 2025 USA News Group News Commentary  Issued on behalf of Avant Technologies...

17 Janvier 2025
PR Newswire (US)

Form 144 - Report of proposed sale of securities

17 Janvier 2025
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

15 Janvier 2025
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

14 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

13 Janvier 2025
Edgar (US Regulatory)

Form 8-K - Current report

13 Janvier 2025
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

10 Janvier 2025
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

08 Janvier 2025
Edgar (US Regulatory)

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors...

07 Janvier 2025
GlobeNewswire Inc.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.94514.40548780496.568.266.48184179757.17185755CS
4-0.095-1.257.68.666.2153458917.10801618CS
121.14518.00314465416.369.555.61137535867.00383322CS
26-0.845-10.1197604798.359.555.6186188856.93015185CS
52-3.335-30.765682656810.8415.745.6172600498.16054529CS
156-3.645-32.690582959611.1516.7454.5440865658.70921512CS
260-22.495-74.98333333333042.814.5434270289.42072149CS

RXRX - Frequently Asked Questions (FAQ)

What is the current Recursion Pharmaceuticals share price?
The current share price of Recursion Pharmaceuticals is US$ 7,505
How many Recursion Pharmaceuticals shares are in issue?
Recursion Pharmaceuticals has 286 640 833 shares in issue
What is the market cap of Recursion Pharmaceuticals?
The market capitalisation of Recursion Pharmaceuticals is USD 2,16B
What is the 1 year trading range for Recursion Pharmaceuticals share price?
Recursion Pharmaceuticals has traded in the range of US$ 5,61 to US$ 15,74 during the past year
What is the PE ratio of Recursion Pharmaceuticals?
The price to earnings ratio of Recursion Pharmaceuticals is -6,67
What is the cash to sales ratio of Recursion Pharmaceuticals?
The cash to sales ratio of Recursion Pharmaceuticals is 49,07
What is the reporting currency for Recursion Pharmaceuticals?
Recursion Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Recursion Pharmaceuticals?
The latest annual turnover of Recursion Pharmaceuticals is USD 44,58M
What is the latest annual profit for Recursion Pharmaceuticals?
The latest annual profit of Recursion Pharmaceuticals is USD -328,07M
What is the registered address of Recursion Pharmaceuticals?
The registered address for Recursion Pharmaceuticals is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Recursion Pharmaceuticals website address?
The website address for Recursion Pharmaceuticals is www.recursion.com
Which industry sector does Recursion Pharmaceuticals operate in?
Recursion Pharmaceuticals operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
NVNINVNI Group Ltd
US$ 4,8303
(224,18%)
310,46M
CREVCarbon Revolution Public Ltd
US$ 7,26
(97,28%)
3,03M
GOEVCanoo Inc
US$ 0,6157
(86,58%)
254,82M
PCLAPicoCELA Inc
US$ 5,04
(63,64%)
2,87M
NEUPNeuphoria Therapeutics Inc
US$ 5,5623
(59,38%)
23,28M
GODNUGolden Star Acquisition Corporation
US$ 3,30
(-74,34%)
7,45k
GODNGolden Star Acquisition Corporation
US$ 2,87
(-66,37%)
115,56k
NXTTNext Technology Holding Inc
US$ 1,46
(-51,97%)
1,85M
SGLYSingularity Future Technology Ltd
US$ 1,6336
(-38,12%)
778,9k
WHLRLWheeler Real Estate Investment Trust Inc
US$ 90,11
(-38,07%)
8
ACONAclarion Inc
US$ 0,0623
(44,21%)
706,62M
NVNINVNI Group Ltd
US$ 4,8499
(225,50%)
310,52M
GOEVCanoo Inc
US$ 0,61565
(86,56%)
254,82M
RIMEAlgorhythm Holdings Inc
US$ 0,0371
(8,80%)
242,01M
RGTIRigetti Computing Inc
US$ 13,78
(2,30%)
178,19M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
RXRX
Recursion Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés